Interim estimates of the effectiveness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2014

Eurosurveillance

Volumn 19, Issue 42, 2014, Pages

  Turner, N ^a   Pierse, N ^b   Huang, Q S ^c   Radke, S ^a,c   Bissielo, A ^c   Thompson, M G ^d   Kelly, H ^e,f   Adlam, Bruce ^g   Aley, Debbie ^g   Baker, Michael ^g   Bandaranayake, Don ^g   Cameron, John ^g   Davey, Kirstin ^g   Davies, Gillian ^g   Duque, Jazmin ^g   LeaneEls, ^g   Grant, Cameron C ^g   Gordon, Rosemary ^g   Gross, Diane ^g   Howie, Marion ^g   Lawrence, Shirley ^g   Mackereth, Graham ^g   McArdle, Barbara ^g   McArthur, Colin ^g   Metz, Thomas ^g   Reynolds, Gary ^g   Roberts, Sally ^g   Seeds, Ruth ^g   Taylor, Susan ^g   Thomas, Paul ^g   Trenholme, Adrian ^g   Webby, Richard ^g   Williamson, Deborah A ^g   Widdowson, Marc Alain ^g   Wong, Conroy ^g   Wood, Tim ^g   Wong, Sam ^g   more..

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^f VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COUGHING; FEVER; HOSPITALIZATION; HUMAN; INFANT; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MAJOR CLINICAL STUDY; MIDDLE AGED; NEW ZEALAND; PRIMARY MEDICAL CARE; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY TRACT INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84908528902     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES2014.19.42.20934     Document Type: Article

References (14)

1. Huang QS, Baker M, McArthur C, Roberts S, Williamson D, Grant C, et al. Implementing hospital-based surveillance for severe acute respiratory infections caused by influenza and other respiratory pathogens, New Zealand. Western Pac Surveill Response. 2014.;5(2):23-30. http://dx.doi.org/10.5365/wpsar.2014.5.1.004
2. Turner N, Pierse N, Bissielo A, Huang QS, Baker MG, Widdowson MA, et al. The effectiveness of seasonal trivalent inactivated influenza vaccine in preventing laboratory confirmed influenza hospitalisations in Auckland, New Zealand in 2012. Vaccine. 2014;32(29):3687-93. http://dx.doi.org/10.1016/j.vaccine.2014.04.013
3. Turner N, Pierse N, Bissielo A, Huang Q, Radke S, Baker M, et al. Effectivness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2013. EuroSurveill. 2014;19(34): 20884.
4. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2014 southern hemisphere influenza season. 26 September 2013. Geneva: WHO; 2013. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/2014_south/en/
5. Shu B, Wu KH, Emery S, Villanueva J, Johnson R, Guthrie E, et al. Design and performance of the CDC real-time reverse transcriptase PCR swine flu panel for detection of 2009 A (H1N1) pandemic influenza virus. J Clin Microbiol. 2011;49(7):2614-9. http://dx.doi.org/10.1128/JCM.02636-10
6. Szewczuk E, Thapa K, Anninos T, McPhie K, Higgins G, Dwyer DE, et al. Rapid semi-automated quantitative multiplex tandem PCR (MT-PCR) assays for the differential diagnosis ofinfluenzalike illness. BMC Infect Dis. 2010;10:113. http://dx.doi.org/10.1186/1471-2334-10-113
7. World Health Organization (WHO). WHO_global_influenza_surveillance:network: manual for the laboratory diagnosis and virological surveillance of influenza. Geneva: WHO; 2011.p. 153. Available from: http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf
8. Crampton P, Salmon C, Kirkpatrick R. Degrees of deprivation in New Zealand: an atlas of socioeconomic difference. 2nd ed. Auckland: David Bateman Ltd; 2004.
9. Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ.1993;306(6890): p. 1437-40. http://dx.doi.org/10.1136/bmj.306.6890.1437
10. McNeil S, Shinde V, Andrew M, Hatchette T, Leblanc J, Ambrose A, et al. Interim estimates of 2013/14 influenza clinical severity and vaccine effectiveness in the prevention of laboratory- confirmed influenza-related hospitalisation, Canada, February 2014. Euro Surveill. 2014;19(9): 20729.
11. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson J, Winter A, et al. Interim estimates of 2013/14 vaccine effectiveness against influenza A (H1N1) pdm09 from Canada’s sentinel surveillance network, January 2014. Euro Surveill. 2014;19(5): 20690.
12. Flannery B, Thaker SN, Clippard J, Monto AS, Ohmit SE, Zimmerman RK, et al. Interim estimates of 2013-14 seasonal influenza vaccine effectiveness-United States, February 2014. MMWR Morb Mortal Wkly Rep. 2014;63(7):137-42.
13. Jimenez-Jorge S, Pozo F, de Mateo S, Delgado-Sanz C, Casas I, Garcia-Cenoz M, et al. Influenza vaccine effectiveness in Spain 2013/14: subtype-specific early estimates using the cycEVA study. Euro Surveill. 2014,19(9): 20727.
14. World Health Organization (WHO). WHO recommendations on the composition of influenza virus vaccines. Geneva: WHO. [Accessed 22 Oct 2014]. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/en/